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Abstract
Current test-of-cure practice in patients with Chlamydia trachomatis (Ct) infection is to confirm cure with a single test taken
at least 3 weeks after treatment. Effectiveness of single-time-point testing however lacks a scientific evidence basis and the
high sensitivity of laboratory assays nowadays in use for this purpose may compromise the clinical significance of their
results. Prospectively following 59 treated Ct infections, administering care as usual, the presence of Ct plasmid DNA and
rRNA was systematically assessed by multiple time-sequential measurements, i.e. on 18 samples taken per patient during 8
weeks following treatment with a single dose of 1000 mg Azythromycin. A high proportion (42%) of Ct infections tested
positive on at least one of the samples taken after 3 weeks. Patients’ test results showed substantial inter-individual and
intra-individual variation over time and by type of NAAT used. We demonstrated frequent intermittent positive patterns in
Ct test results over time, and strongly argue against current test-of-cure practice.
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Introduction
Current treatment practice in Chlamydia trachomatis (Ct) infec-
tions is challenged by a growing concern over the efficacy of
Azythromycin, currently the recommended antibiotic treatment
[1,2,3]. Data indicating sub-optimal effectiveness were presented
at the recent meeting of the International Society for Sexually
Transmitted Diseases Research (Que ´bec, Canada July 2011) [4]. It
was also noted that assessment of actual treatment failure is
hampered by the difficulty to differentiate between re-infection
and antibiotic resistance in vivo. To confirm clearance of Ct
infection, and thus deliver a proof of cure, clinicians can apply a
single time-point test-of-cure, using nucleic acid amplification
assays (NAAT). There are currently no data available on the
optimal timing of testing for cure; generally, testing no sooner than
3 weeks and no later than 3 months after treatment is
recommended [1,2]. Current guidelines by the Centers for Disease
Control and Prevention, advocate restricted use of a test-of-cure,
i.e. only when a patient is pregnant, therapeutic compliance is
questioned, symptoms persist, or re-infection is suspected [1]. Data
on the actual use of a test-of-cure are scarce, although results from
a recent large-scale US study among women suggested inadequate
adherence to current testing guidelines [5]. Nevertheless, there are
data suggesting that test-of-cure practices are by no means
uncommon. In The Netherlands for example, 11% of men and
27% of women with an initial Ct-positive test were retested within
the first 3 months (unpublished South Limburg laboratory registry
data). In the US, 21% of all repeat Ct tests in women between 15
and 25 years of age who were enrolled in commercial health plans
and had two or more Ct tests, were performed within the second
and third month (personal communication J. Heijne, MSc. 2012
University of Bern, Bern, Switzerland). It should be noted though,
that in this latter dataset the result of the initial Ct test and reason
for testing were unknown [6].
Effectiveness of the current test-of-cure practices using single-
time-point testing however lacks a scientific evidence basis. The
current practice of using highly sensitive NAAT for test-of-cure
practice has several well-known shortcomings [7]. A positive result
may reflect treatment failure with persistent infection, but may also
reflect resolved infection by detecting the mere presence of
ribosomal RNA debris and non-viable Ct DNA [8]. Other possible
explanations include detection of re-infection or transient Ct DNA
after sex with an infected partner. Even in persistent infection, a
positive test may be preceded by a negative post-treatment NAAT
[9,10]. The clinical conundrum of delivering a proof of cure is
further addressed here. We explored consistency in individual test-
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34108Figure 1. Cervicovaginal (a) and anorectal (b) Chlamydia trachomatis rRNA and DNA detection between 23 and 51 days post directly
observed Azythromycin treatment. Each row represents a cervicovaginal or anorectal Ct infection. Twenty five infections (out of 59) had at least
one positive sample between 23 and 51 days post-treatment and these 25 infections are displayed here. Self taken swabs were tested for Ct rRNA
(TMA, Tigris; GenProbe, San Diego, US) and plasmid DNA (real-time in house PCR; Amsterdam, the Netherlands) [12].
doi:10.1371/journal.pone.0034108.g001
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to reflect actual test-of-cure practices. In a cohort of Ct treated
patients, we systematically assessed the presence of Ct plasmid
DNA and rRNA by multiple time-sequential measurements on 18
samples per Ct infection taken during 8 weeks following treatment
with a single dose of 1000 mg Azythromycin.
Results
Taking a test-of-cure at 23, 26, 30, 37, 44 and 51 days post-
treatment, 14%, 20%, 16%, 17%, 22% and 24%, respectively, of
the 59 Ct infections tested positive for rRNA and/or DNA.
Overall, 42% (n=25) of the Ct infections tested positive on at least
one of the samples taken between 23 and 51 days; 42% (n=25)
tested positive for rRNA and 27% (n=16) for DNA. The test
results of these 25 infections showed substantial inter-individual
and intra-individual variation over time and by type of NAAT
used, as is shown in Fig. 1. Most infections tested positive
intermittently. Inadequate self-sampling seemed unlikely as a
possible explanation for intermediary Ct-negative tests as human
DNA was detected in the majority of Ct-negative samples; samples
from 3 Ct infections did not contain human DNA. One
cervicovaginal and 4 anorectal Ct infections consistently tested
rRNA-positive, of which 2 anorectal infections also tested Ct
DNA-positive in all samples taken between 23 and 51 days post
treatment. In total, 66% of the 59 Ct infections demonstrated test
results that were consistently negative (n=34) or positive (n=5) for
Ct rRNA and/or DNA between 23 and 51 days post treatment.
Discussion
Given the pattern of intermittent positive results and substantial
variability between different types of NAAT used, it seems
unjustified to interpret a single positive NAAT taken between 3
to 8 weeks post-treatment as treatment failure/persistence or (re-
)infection. Likewise, the clinical significance of a single negative
NAAT may be debatable. Our results reinforce the known
difficulties in establishing a proof of cure. A positive NAAT may
occur due to treatment failure, but also due to other causes. A
negative NAAT may indicate cleared infection, but may also
reflect persistent infection. Sexual history is not a reliable tool to
confirm or rule out new Ct infection, and at present there are no
specific laboratory tests that allow clinicians to reliably distinguish
between treatment failure/persistence or resistance. It is a real,
perhaps even insurmountable, challenge to overcome this
problem.
Yet, in current clinical practice a single time-point test-of-cure
by NAAT is taken to reflect a patient’s Ct clearance status.
Alongside the positive aspects, i.e. reassurance of worried patients
and, sometimes, more adequate treatment, the negative conse-
quences of current test-of-cure practices - including unnecessary
antibiotic treatment and laboratory testing - should not be
overlooked. Considering that clinical significance of a positive
test-of-cure by NAAT is unknown, sequential rather than single-
time point testing may not solve the problem either. The
individual and public health gains and cost-effectiveness of test-
of-cure practices by NAAT remain to be established. Treatment
practice may need to focus more on improving compliance of the
patient and their partners in treatment with state-of-the-art
regimens [11] and increasing the proportion of patients re-tested
after 3 to 12 months, in accordance with current recommenda-
tions [1,2].
Methods
Ethics statement
The study was ethically approved by the Medical Ethics
Committee at the Free University of Amsterdam (UvA:2009/
154,CCMO The Hague:NL28609.029.09). Clinicaltrials.gov
Identifier: NCT01448876.
Study population and setting
By convenience sampling at our outpatient STD clinic (South
Limburg, the Netherlands), 46 non-pregnant women and 6 men
were included, contributing 44 cervicovaginal and 15 anorectal
infections; 7 women contributed infections from both anatomic
sites. Participants provided a total of 1016 self-taken cervicovaginal
and/or anorectal swabs taken over a period from 0 until 51 days
post-treatment, at pre-defined points of time. Overall, 94% of
samples were delivered according to schedule, and were laboratory
tested. All patients were negative for HIV, gonorrhea and
Lymphogranuloma venerum (the latter was tested in anorectal Ct-
positive samples only). Usual care recommending abstinence or
safe sex for one week and providing treatment for steady partners
was administered [1,2]. Participants provided written informed
consent.
Analyses
Swabs were tested for Ct rRNA (TMA, Tigris; GenProbe, San
Diego, US) and plasmid DNA (real-time in house PCR;
Amsterdam, the Netherlands) [12]. All Ct-negative samples taken
at the 2 time points preceding and following a Ct-positive sample
between 16 and 51 days post-treatment were re-tested for human
DNA to rule out that a negative result was due to inadequate
sampling. Test results of samples not containing human DNA
were considered missing in analyses. The proportion of rRNA
and/or DNA-positive samples was assessed during 23 and 51 days
post-treatment
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